Anti-Depressants

Dr.Harim Mohsin
First things first


Depression is a medical condition & not any fault of the
individual concerned.



Assessment & evaluation is mandatory-Severity, etiology
& risk-factors.



Treatment plan comprises of medication, psychological &
social support.
Indications


Depression
Moderate-Severe, Atypical, SAD, Depressive episode of
Bipolar disorder.



Anxiety disorders
GAD, Panic Disorder, Social Anxiety, Adjustment disorders,
Agoraphobia, OCD, PTSD.
Mode of Action
Mode of action
All antidepressants function by increasing availability
of monoamines (5-HT, NA or DA) by one of the
following methods:


Presynaptic inhibition of reuptake of 5-HT, NA or DA.



Antagonist activity at presynaptic inhibitory 5HT or NA
receptors which enhances neurotransmitter release.



Inhibition of Monoaminase oxidase, reducing NT
breakdown.



Increasing availability of NT precursors.

Initial resolution of depressive symptoms takes minimum
of 2-4 weeks.
Classification
Broadly into 2 Types:
 Re-uptake

Inhibitors
 Enzyme Inhibitors
Classification


Selective serotonin reuptake inhibitors
(SSRIs)

Monoamine oxidase inhibitors (MAOIs)
–
–



Serotonin-norepinephrine reuptake
inhibitors (SNRIs)

Irreversible
Reversible




Norepinephrine reuptake inhibitors
(NRIs)



Tricyclic antidepressants (TCAs)



Norepinephrine-dopamine reuptake
inhibitors (NDRIs)



Serotonin antagonist and reuptake
inhibitors (SARIs)

Noradrenergic and specific serotonergic
antidepressant (NaSSA)



Tetracyclic antidepressants (TeCAs)
SSRIs (Selective serotonin reuptake inhibitors)
Mechanism: Increases 5HT in synaptic cleft.


Citalopram (Cipram)



Escitalopram (Cipralex, Citanew, Neolexa)



Paroxetine (Paroxin, Seroxat)



Fluoxetine (Prozac, Depex)



Fluvoxamine (Faverin)



Sertraline (Zoloft, Sert):
Indications
 Depression
 Panic

Disorder with agoraphobia
 Social Anxiety/ GAD/ OCD
 Bulimia
 PTSD
Side-effects









GI discomfort/ nausea
Sexual dysfunction
Sleep disturbance
Dry mouth
Tremor
Headache
Anxiety/ restlessness.
Fatigue

Caution:
 Be aware of
interactions-inhibitory
effects on P450 &
changes with alcohol,
anticoagulants, MAOIs,
TCA, smoking etc.
TCA Mechanism
Mechanism:
 Reuptake inhibition
NA, 5HT & DA.
TCAs (Tricyclic antidepressants )
 Amitriptyline

(Tryptanol)
 Clomipramine (Clomfranil)
 Desipramine (Norpramin,Pertofrane)
 Dosulepin (Prothiaden)
 Doxepin (Doxin)
 Imipramine (Tofranil, Imidol)
 Nortriptyline (Sensival)
Indications
 Depression
 Nocturnal

Enuresis (Amitriptyline/
Imipramine)

 Phobic/Obsessional
 Cataplexy

States

with narcolepsy
Side-effects








Dry mouth,
Caution:
Blurred vision,
 Arrhythmias & ECG
Sedation,
changes. Monitor
Orthostatic hypotension,
Cardiac function, LFTs,
Constipation,
UCEs.
urinary incontinence.
Disorientation or
 Should be used
confusion
cautiously in elderly.
SNRIs (Serotonin-norepinephrine reuptake
inhibitors )
Mechanism: Similar to SSRI, Inhibit 5HT & NA (high doses DA)
Indications: GAD, Depression.


Venlafaxine (Efexor)



Duloxetine (Oxcym DR, Hapibar, Lyta)



Levomilnacipran (Fetzima)



Tramadol (Tramal, Ultram)



Sibutramine (Meridia, Reductil)

Side-effects: Similar to SSRIs & may cause HTN.
MAOIs (Monoamine oxidase inhibitors)




Irreversible inhibition of MAO-A
(acts on NA, DA, 5HT & Tyramine) &
MAO-B (acts on DA, Tyramine,
Phenylethylamine, benzylamine)
leading to accumulation of
monoamines in Synaptic Cleft.

 RIMAs: Reversible inhibition
of MAO-A.
Indications
 Depression

(atypical)



Parkinson's Disease,



Migraine prophylaxis



Other disorders: panic disorder with agoraphobia,
social phobia, bulimia, PTSD, borderline personality
disorder, and bipolar depression.
MAOIs (Monoamine oxidase inhibitors)
Irreversible
 Isocarboxazid (Marplan)
 Phenelzine (Nardil)
 Selegiline (Selgin, Eklin)
Reversible
 Moclobemide (Aurorix,
Manerix)
 Pirlindole (Pirazidol)
MOA Inhibitors- Say No.
Side-Effects


Hypertensive crisis



Dizziness/ Headaches



Hepatotoxicity



Sleep disturbance



Weight gain



Sexual dysfunction



Drug Interactions

Caution:
 Dietary restriction
(Tyramine) e.g: cheese,
chocolate, wine, beans &
soy products.


Serotonin Syndrome: Lifethreatening condition with
somatic, autonomic &
cognitive effectsTachycardia, myoclonus,
tremors, altered Mental
status, hyperthermia, DIC,
metabolic disturbances.
Tetracyclic antidepressants (TeCAs)
Mode: Similar to TCA without anticholinergic SE
Indications: TCA with sedation.
S/E- Cardiotoxicity





Mirtazapine (Remeron)
Mianserin (Bolvidon, Norval, Tolvon)
Amoxapine (Asendin)
Maprotiline (Ludiomil)

Noradrenergic and specific serotonergic antidepressant (NaSSA)
Mode: α2 inhibitor (^NA/5HT), 5HT1, 5HT2 antagonist.
Indications: Depression (+anxiety,wt loss) adjunct SSRI/venlafaxine to improve
SxD, GI discomfort.
Advantages: Low Toxicity, less sexual dysfunction & GI upset.
(SARIs)

Serotonin antagonist and reuptake inhibitors
Mode: 5HT reuptake inhibitor & antagonist.
(sedation/ antihistamine)
Indication: Depression (+insomnia) / Anxiety
Advantage: Less antimuscranic/ cardiotoxic than TCA.
 Trazodone

(Deprel)
 Etoperidone (Axiomin, Etonin)
 Nefazodone (Serzone, Nefadar)
Other anti-depressants


Norepinephrine-dopamine reuptake inhibitors (NDRIs)

Mode: NA/DA reuptake inhibition
Indications: Depression (with marked psychomotor retardation or hypersomnia),
Nicotine/stimulants dependence, ADHD.
Advantage: Unusual mode of action-alerting effects, controls impulse disorders &
secondary benefits as AD.
S/E: Seizures & hypersensitivity.


Bupropion (Wellbutrin, Zyban)
Other anti-depressants


Norepinephrine reuptake inhibitors (NRIs)-

Indication: Atypical Depression

Reboxetine (Edronax)
Adjunctive treatments
Itself doesn’t possess antidepressant quality but works in combination.
Atypical antipsychotics
 Aripiprazole (Aripip)
 Olanzapine (Olanzia,Amprexa)
 Quetiapine (Qusel)
 Risperidone (Risperdal,Persch, Neoris)






Others
Carbamazepine
Lamotrigine (Lamictal)
Lithium salts
Triiodothyronine (T3; a thyroid hormone)
Alternate treatments
Psychotherapy / counseling
 Phytotherapy: St-John’s Wort
 Exercise
 Nutritional Supplements- Vitamins, minerals, O3-FA.
 Adequate sleep.
 Avoid Alcohol & other recreational drugs
 Meditation, Acupuncture, chiropractice & yoga.

Think Positive!

Thank You

Anti depressants

  • 1.
  • 2.
    First things first  Depressionis a medical condition & not any fault of the individual concerned.  Assessment & evaluation is mandatory-Severity, etiology & risk-factors.  Treatment plan comprises of medication, psychological & social support.
  • 3.
    Indications  Depression Moderate-Severe, Atypical, SAD,Depressive episode of Bipolar disorder.  Anxiety disorders GAD, Panic Disorder, Social Anxiety, Adjustment disorders, Agoraphobia, OCD, PTSD.
  • 4.
  • 5.
    Mode of action Allantidepressants function by increasing availability of monoamines (5-HT, NA or DA) by one of the following methods:  Presynaptic inhibition of reuptake of 5-HT, NA or DA.  Antagonist activity at presynaptic inhibitory 5HT or NA receptors which enhances neurotransmitter release.  Inhibition of Monoaminase oxidase, reducing NT breakdown.  Increasing availability of NT precursors. Initial resolution of depressive symptoms takes minimum of 2-4 weeks.
  • 6.
    Classification Broadly into 2Types:  Re-uptake Inhibitors  Enzyme Inhibitors
  • 7.
    Classification  Selective serotonin reuptakeinhibitors (SSRIs) Monoamine oxidase inhibitors (MAOIs) – –  Serotonin-norepinephrine reuptake inhibitors (SNRIs) Irreversible Reversible   Norepinephrine reuptake inhibitors (NRIs)  Tricyclic antidepressants (TCAs)  Norepinephrine-dopamine reuptake inhibitors (NDRIs)  Serotonin antagonist and reuptake inhibitors (SARIs) Noradrenergic and specific serotonergic antidepressant (NaSSA)  Tetracyclic antidepressants (TeCAs)
  • 8.
    SSRIs (Selective serotoninreuptake inhibitors) Mechanism: Increases 5HT in synaptic cleft.  Citalopram (Cipram)  Escitalopram (Cipralex, Citanew, Neolexa)  Paroxetine (Paroxin, Seroxat)  Fluoxetine (Prozac, Depex)  Fluvoxamine (Faverin)  Sertraline (Zoloft, Sert):
  • 9.
    Indications  Depression  Panic Disorderwith agoraphobia  Social Anxiety/ GAD/ OCD  Bulimia  PTSD
  • 10.
    Side-effects         GI discomfort/ nausea Sexualdysfunction Sleep disturbance Dry mouth Tremor Headache Anxiety/ restlessness. Fatigue Caution:  Be aware of interactions-inhibitory effects on P450 & changes with alcohol, anticoagulants, MAOIs, TCA, smoking etc.
  • 11.
    TCA Mechanism Mechanism:  Reuptakeinhibition NA, 5HT & DA.
  • 12.
    TCAs (Tricyclic antidepressants)  Amitriptyline (Tryptanol)  Clomipramine (Clomfranil)  Desipramine (Norpramin,Pertofrane)  Dosulepin (Prothiaden)  Doxepin (Doxin)  Imipramine (Tofranil, Imidol)  Nortriptyline (Sensival)
  • 13.
    Indications  Depression  Nocturnal Enuresis(Amitriptyline/ Imipramine)  Phobic/Obsessional  Cataplexy States with narcolepsy
  • 14.
    Side-effects        Dry mouth, Caution: Blurred vision, Arrhythmias & ECG Sedation, changes. Monitor Orthostatic hypotension, Cardiac function, LFTs, Constipation, UCEs. urinary incontinence. Disorientation or  Should be used confusion cautiously in elderly.
  • 15.
    SNRIs (Serotonin-norepinephrine reuptake inhibitors) Mechanism: Similar to SSRI, Inhibit 5HT & NA (high doses DA) Indications: GAD, Depression.  Venlafaxine (Efexor)  Duloxetine (Oxcym DR, Hapibar, Lyta)  Levomilnacipran (Fetzima)  Tramadol (Tramal, Ultram)  Sibutramine (Meridia, Reductil) Side-effects: Similar to SSRIs & may cause HTN.
  • 16.
    MAOIs (Monoamine oxidaseinhibitors)   Irreversible inhibition of MAO-A (acts on NA, DA, 5HT & Tyramine) & MAO-B (acts on DA, Tyramine, Phenylethylamine, benzylamine) leading to accumulation of monoamines in Synaptic Cleft.  RIMAs: Reversible inhibition of MAO-A.
  • 17.
    Indications  Depression (atypical)  Parkinson's Disease,  Migraineprophylaxis  Other disorders: panic disorder with agoraphobia, social phobia, bulimia, PTSD, borderline personality disorder, and bipolar depression.
  • 18.
    MAOIs (Monoamine oxidaseinhibitors) Irreversible  Isocarboxazid (Marplan)  Phenelzine (Nardil)  Selegiline (Selgin, Eklin) Reversible  Moclobemide (Aurorix, Manerix)  Pirlindole (Pirazidol)
  • 19.
  • 20.
    Side-Effects  Hypertensive crisis  Dizziness/ Headaches  Hepatotoxicity  Sleepdisturbance  Weight gain  Sexual dysfunction  Drug Interactions Caution:  Dietary restriction (Tyramine) e.g: cheese, chocolate, wine, beans & soy products.  Serotonin Syndrome: Lifethreatening condition with somatic, autonomic & cognitive effectsTachycardia, myoclonus, tremors, altered Mental status, hyperthermia, DIC, metabolic disturbances.
  • 21.
    Tetracyclic antidepressants (TeCAs) Mode:Similar to TCA without anticholinergic SE Indications: TCA with sedation. S/E- Cardiotoxicity     Mirtazapine (Remeron) Mianserin (Bolvidon, Norval, Tolvon) Amoxapine (Asendin) Maprotiline (Ludiomil) Noradrenergic and specific serotonergic antidepressant (NaSSA) Mode: α2 inhibitor (^NA/5HT), 5HT1, 5HT2 antagonist. Indications: Depression (+anxiety,wt loss) adjunct SSRI/venlafaxine to improve SxD, GI discomfort. Advantages: Low Toxicity, less sexual dysfunction & GI upset.
  • 22.
    (SARIs) Serotonin antagonist andreuptake inhibitors Mode: 5HT reuptake inhibitor & antagonist. (sedation/ antihistamine) Indication: Depression (+insomnia) / Anxiety Advantage: Less antimuscranic/ cardiotoxic than TCA.  Trazodone (Deprel)  Etoperidone (Axiomin, Etonin)  Nefazodone (Serzone, Nefadar)
  • 23.
    Other anti-depressants  Norepinephrine-dopamine reuptakeinhibitors (NDRIs) Mode: NA/DA reuptake inhibition Indications: Depression (with marked psychomotor retardation or hypersomnia), Nicotine/stimulants dependence, ADHD. Advantage: Unusual mode of action-alerting effects, controls impulse disorders & secondary benefits as AD. S/E: Seizures & hypersensitivity.  Bupropion (Wellbutrin, Zyban)
  • 24.
    Other anti-depressants  Norepinephrine reuptakeinhibitors (NRIs)- Indication: Atypical Depression Reboxetine (Edronax)
  • 25.
    Adjunctive treatments Itself doesn’tpossess antidepressant quality but works in combination. Atypical antipsychotics  Aripiprazole (Aripip)  Olanzapine (Olanzia,Amprexa)  Quetiapine (Qusel)  Risperidone (Risperdal,Persch, Neoris)      Others Carbamazepine Lamotrigine (Lamictal) Lithium salts Triiodothyronine (T3; a thyroid hormone)
  • 26.
    Alternate treatments Psychotherapy /counseling  Phytotherapy: St-John’s Wort  Exercise  Nutritional Supplements- Vitamins, minerals, O3-FA.  Adequate sleep.  Avoid Alcohol & other recreational drugs  Meditation, Acupuncture, chiropractice & yoga. 
  • 27.